Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Manuel Anguita

Showing results (201-210 of 266) with videos related to

Pageof 27
Sort By:
Cardiology Journal|May 27, 2022
Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR studyMarcelo Sanmartín Fernández, Manuel Anguita Sánchez, Fernando Arribas, et al.
Journal of Clinical Medicine|September 4, 2020
Gender Differences in Health-Related Quality of Life in Patients with Systolic Heart Failure: Results of the VIDA Multicenter StudyAlberto Garay, Javier Tapia, Manuel Anguita, et al.
European Journal of Clinical Investigation|November 10, 2021
Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP-AF Long-term General RegistryAlejandro I Pérez Cabeza, José Miguel Rivera-Caravaca, Inmaculada Roldán-Rabadán, et al.
Revista Espanola De Cardiologia (English Ed.)|October 1, 2018
Long-term Survival in a Spanish Population With Stable Ischemic Heart Disease. The CICCOR RegistryJosé Javier Sánchez Fernández, Martín Ruiz Ortiz, Cristina Ogayar Luque, et al.
Journal of Comparative Effectiveness Research|February 7, 2023
Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxabanFrancisco Marín, Marcelo Sanmartín Fernández, Gonzalo Barón-Esquivias, et al.
Cardiology Journal|October 6, 2022
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR studyManuel Anguita Sánchez, Francisco Marín, Jaime Masjuan, et al.
European Journal of Clinical Investigation|April 8, 2022
Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR studyRaquel López-Gálvez, José Miguel Rivera-Caravaca, Manuel Anguita Sánchez, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|August 10, 2021
Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General RegistryJosé Miguel Rivera-Caravaca, Olivier Piot, Inmaculada Roldán-Rabadán, et al.
Revista Espanola De Cardiologia (English Ed.)|September 20, 2024
The European Society of Cardiology quality indicators in atrial fibrillation in centers of excellence in Spain: the SEC-EXCELENTE FA registryMartín Ruiz Ortiz, Elena Arbelo, Inmaculada Roldán Rabadán, et al.
European Heart Journal|August 30, 2024
Colchicine in acutely decompensated heart failure: the COLICA trialDomingo Pascual-Figal, Julio Núñez, Maria T Pérez-Martínez, et al.
Pageof 27

Showing results (201-210 of 266) with videos related to

Sort By:
Pageof 27
Cardiology Journal|May 27, 2022
Outcomes and predictive value of the 2MACE score in patients with atrial fibrillation treated with rivaroxaban in a prospective, multicenter observational study: The EMIR studyMarcelo Sanmartín Fernández, Manuel Anguita Sánchez, Fernando Arribas, et al.
Journal of Clinical Medicine|September 4, 2020
Gender Differences in Health-Related Quality of Life in Patients with Systolic Heart Failure: Results of the VIDA Multicenter StudyAlberto Garay, Javier Tapia, Manuel Anguita, et al.
European Journal of Clinical Investigation|November 10, 2021
Antithrombotic therapy and clinical outcomes at 1 year in the Spanish cohort of the EORP-AF Long-term General RegistryAlejandro I Pérez Cabeza, José Miguel Rivera-Caravaca, Inmaculada Roldán-Rabadán, et al.
Revista Espanola De Cardiologia (English Ed.)|October 1, 2018
Long-term Survival in a Spanish Population With Stable Ischemic Heart Disease. The CICCOR RegistryJosé Javier Sánchez Fernández, Martín Ruiz Ortiz, Cristina Ogayar Luque, et al.
Journal of Comparative Effectiveness Research|February 7, 2023
Non-embolic outcomes in patients with cardiovascular disease and atrial fibrillation treated with rivaroxabanFrancisco Marín, Marcelo Sanmartín Fernández, Gonzalo Barón-Esquivias, et al.
Cardiology Journal|October 6, 2022
Impact of heart failure on the clinical profile and outcomes in patients with atrial fibrillation treated with rivaroxaban. Data from the EMIR studyManuel Anguita Sánchez, Francisco Marín, Jaime Masjuan, et al.
European Journal of Clinical Investigation|April 8, 2022
Use of rivaroxaban attenuates renal function impairment in patients with atrial fibrillation: insights of the EMIR studyRaquel López-Gálvez, José Miguel Rivera-Caravaca, Manuel Anguita Sánchez, et al.
Europace : European Pacing, Arrhythmias, and Cardiac Electrophysiology : Journal of the Working Groups on Cardiac Pacing, Arrhythmias, and Cardiac Cellular Electrophysiology of the European Society of Cardiology|August 10, 2021
Characterization of atrial fibrillation in real-world patients: testing the 4S-AF scheme in the Spanish and French cohorts of the EORP-AF Long-Term General RegistryJosé Miguel Rivera-Caravaca, Olivier Piot, Inmaculada Roldán-Rabadán, et al.
Revista Espanola De Cardiologia (English Ed.)|September 20, 2024
The European Society of Cardiology quality indicators in atrial fibrillation in centers of excellence in Spain: the SEC-EXCELENTE FA registryMartín Ruiz Ortiz, Elena Arbelo, Inmaculada Roldán Rabadán, et al.
European Heart Journal|August 30, 2024
Colchicine in acutely decompensated heart failure: the COLICA trialDomingo Pascual-Figal, Julio Núñez, Maria T Pérez-Martínez, et al.
Pageof 27